Acura Pharmaceuticals (ACUR): Price and Financial Metrics


Acura Pharmaceuticals (ACUR)

Today's Latest Price: $0.24 USD

0.01 (-5.50%)

Updated Dec 4 10:00pm

Add ACUR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 369 in Miscellaneous

See all "A" rated Strong Buy stocks

ACUR Stock Summary

  • With a market capitalization of $6,495,088, Acura Pharmaceuticals Inc has a greater market value than just 3.07% of US stocks.
  • Acura Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 5.93% of US listed stocks.
  • As for revenue growth, note that ACUR's revenue has grown 171.47% over the past 12 months; that beats the revenue growth of 96.4% of US companies in our set.
  • Stocks that are quantitatively similar to ACUR, based on their financial statements, market capitalization, and price volatility, are OPGN, TMDX, ESLT, VJET, and EMAN.
  • ACUR's SEC filings can be seen here. And to visit Acura Pharmaceuticals Inc's official web site, go to www.acurapharm.com.

ACUR Stock Price Chart Interactive Chart >

Price chart for ACUR

ACUR Price/Volume Stats

Current price $0.24 52-week high $0.47
Prev. close $0.26 52-week low $0.12
Day low $0.24 Volume 3,900
Day high $0.27 Avg. volume 9,767
50-day MA $0.25 Dividend yield N/A
200-day MA $0.28 Market Cap 5.28M

ACUR Latest News Stream


Event/Time News Detail
Loading, please wait...

ACUR Latest Social Stream


Loading social stream, please wait...

View Full ACUR Social Stream

Latest ACUR News From Around the Web

Below are the latest news stories about Acura Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACUR as an investment opportunity.

Acura Pharmaceuticals reports Q2 results

Acura Pharmaceuticals (ACUR): Q2 GAAP EPS of $0.01.Revenue of $1.4M (+2700.0% Y/Y)Press Release...

Seeking Alpha | August 14, 2020

Acura Pharmaceuticals Announces First Quarter 2020 Financial Results

Acura Pharmaceuticals, Inc. (ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three months ended March 31, 2020. The Company reported revenues of $1.1 million and an operating loss of $483 thousand for the first quarter 2020 compared to revenues of only $67 thousand and an operating loss of $683 thousand for the same period in 2019. The Company reported a net loss of $595 thousand or $0.02 per diluted share for the first quarter 2020 compared to a net loss of $788 thousand or $0.04 per diluted share for the same period in 2019.

Yahoo | June 29, 2020

Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results

PALATINE, Ill., March 30, 2020 -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and.

Yahoo | March 30, 2020

Acura Pharmaceuticals Provides an Update on the Development of LTX-03

Acura Pharmaceuticals, Inc. (ACUR), today announced that Abuse Deterrent Pharma, LLC, its licensee of LTX-03 (Hydrocodone Bitartrate and Acetaminophen with Acura’s LIMITx™ Technology), has engaged Catalent Pharma Solutions, LLC (“Catalent”) to perform tablet manufacturing for clinical testing supplies of the product. Acura previously engaged Catalent to perform micro-particle process development for LTX-03 using hot-melt extrusion technology at Catalent’s Somerset, New Jersey facility before transferring to scaled production in Winchester, Kentucky, and which work is pending receipt of auxiliary manufacturing equipment expected in the next 30 days. Catalent is a leading provider of advanced delivery technologies, development and manufacturing solutions and has the expertise, technolog...

Yahoo | March 23, 2020

Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results

PALATINE, Ill., Feb. 28, 2020 -- Acura Pharmaceuticals, Inc. (OTC: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of.

Yahoo | February 28, 2020

Read More 'ACUR' Stories Here

ACUR Price Returns

1-mo -14.29%
3-mo -14.29%
6-mo -27.27%
1-year -27.05%
3-year -38.46%
5-year -88.63%
YTD 4.35%
2019 100.17%
2018 -71.55%
2017 -47.55%
2016 -69.20%
2015 11.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7715 seconds.